Aptose Biosciences Inc. (APTOF): auditor change — Aptose Biosciences appoints EY as independent auditor, replacing KPMG

Aptose Biosciences Inc.

KPMG informed company it would not stand for re-appointment for 2025 annual audit.
Board approved EY as independent auditor; shareholders voted approval at reconvened meeting on August 22, 2025.
No disagreements or reportable events between company and KPMG during past two fiscal years.
KPMG letter agreeing with disclosures attached as Exhibit 16.1.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Aptose Biosciences Inc. engaged Ernst & Young LLP as its auditor.

Action: engagement
Auditor: Ernst & Young LLP

Exact text from the filing

on August 1, 2025 the Company announced that the Board of Directors (the “Board”) unanimously approved the selection of Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm to serve as the Company’s independent auditor.

View on SEC.gov

Browse all auditor changes →

Aptose Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-189846

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.